US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Omada Health: 2Q’FY25 Net Loss Narrowed, Strong Progress Towards Adj. EBITDA Profitability

Omada Health (OMDA.US): Robust 3Q Undermined by Sentiment, Long-Term Bullish Thesis Intact

Omada Health (OMDA): Second Virtual Healthcare Provider Ready to Test the IPO Market

Omada Health IPO: Stayed Private For Longer, Modest Upside Potential

Omada Health (OMDA): Virtual Healthcare Provider Gains IPO Momentum Behind Success of Peer

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>`Omada Health, Inc. (OMDA) priced a full-size deal of 7.9mm shares at $19.00 (midpoint of the range) and opened at $19.00 for a gain of 21% at first trade.</li>
<li>Omada finished north of 15-times oversubscribed with allocations highly concentrated and skewed to long-only investors.</li>
<li>Our sources stated that the top ten accounts took greater than 50% of the deal and the top 25 took 80% of the transaction.</li>
</ul>


`Omada Health, Inc. (OMDA) priced a full-size deal of 7.9mm shares at $19.00 (midpoint of the range) and opened at $19.00 for a gain of 21% at first trade.
Omada finished north of 15-times oversubscribed with allocations highly concentrated and skewed to long-only investors.
Our sources stated that the top ten accounts took greater than 50% of the deal and the top 25 took 80% of the transaction.


Omada Health (OMDA): Virtual Healthcare Provider Pops 20% After Midpoint Pricing